[1] Stelmach-Goldys A,Czarkowska-Paczek B,Wyczalkowska-Toma-sik A,et al. Serum cystatin C and serum and urine NGAL in the kidney function assessment of patients with MGUS. Eur J Haematol,2015,94(2):162-168. [2] Ermetici F,Filopanti M,Verga U,et al.Estimated glomerular filtration rate by serum cystatin C correlates with cardiometa-bolic parameters in patients with primary hyperparathyroidism. Eur J Endocrinol,2015,173(4):441. [3] 赵萍,翟玉峰,张怀宏. 血清甲胎蛋白和凝血酶原活动度水平对慢加急性肝衰竭患者预后的预测价值研究. 实用肝脏病杂志,2017,20(2):230-231. [4] Li H,Xia Q,Zeng B,et al.Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. J Hepatol,2015,63(1):50-59. [5] Woldu SL,Matulay JT,Silva MV,et al.Serum cystatin C as a novel marker to differentiate pseudoazotemia in the setting of intraperitoneal urine extravasation. Urology,2015,85(4):918-920. [6] Treiber M,Balon B P,Gorenjak M.A new serum cystatin C formula for estimating glomerular filtration rate in newborns. Pediatr Nephrol,2015,30(8):1297-1305. [7] 吴军. 特利加压素与托拉塞米治疗失代偿期肝硬化并发肝肾综合征患者疗效比较. 实用肝脏病杂志,2015,18(1):78-79. [8] Seetlani NK,Memon AR,Iftikhar F,et al.Hepatorenal syndrome in patients with cirrhosis of liver according to 2007 international ascites club criteria. J Ayub Med Coll,2016,28(3):578-581. [9] Yang Y,Zhao X,Tang X,et al.Comparison of serum cystatin C and creatinine level changes for prognosis of patients after peripheral arterial angiography. Angiology,2015,66(8):766-773. [10] 蔡均均,周静,韩涛,等. 血清胱抑素C对肝硬化患者并发急性肾损伤的诊断价值. 中华肝脏病杂志,2017,25(5):157-158. [11] Gustot T,Fernandez J,Garcia E,et al.Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology,2015,62(1):243-252. [12] Shi Y,Yang Y,Hu Y,et al.Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology,2015,62(1):232. [13] Bernsmeier C,Pop OT,Singanayagam A,et al.Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology,2015, 48(3):603. [14] Anna S,Anna T,Mike S,et al.Factors limiting usefulness of serum and urinary NGAL as a marker of acute kidney injury in preterm newborns. Ren Fail,2015,37(3):1-7. [15] 蒋一航,王玮,胡小鹏,等. NGAL与Cys c对于肾移植术后早期肾功能恢复的预测作用. 中华医学杂志,2015,95(2):112-115. [16] Durand F,Graupera I,Ginès P,et al.Pathogenesis of hepatorenal syndrome:Implications for therapy. Am J Kidney Dis,2015,67(2):318-328. [17] Hoková L,Franekova J,Málek I,et al.Comparison of cystatin C and NGAL in early diagnosis of acute kidney injury after heart transplantation. Ann Transpl,2016,21(22):329. [18] Herbert C,Patel M,Nugent A,et al.Serum cystatin C as an early marker of neutrophil gelatinase-associated lipocalin-positive acute kidney injury resulting from cardiopulmonary bypass in infants with congenital heart disease. Congenit Heart Dis,2015,10(4):180-188. [19] Ginès P.Management of hepatorenal syndrome in the era of acute-on-chronic liver failure:Terlipressin and beyond. Gastroenterology,2016,150(7):1525. [20] Cavallin M,Piano S,Romano A,et al.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome:A randomized controlled study. Hepatology,2016,63(3):983. |